NCT02914977View on ClinicalTrials.gov

Low-Dose Daunorubicin in Relapsed/Refractory Acute Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

April 3, 2019

Study Completion Date

July 15, 2021

Conditions
Acute Lymphocytic LeukemiaAcute Myeloid Leukemia
Interventions
DRUG

Daunorubicin

"* Agent: Daunorubicin~* Dose: 6.75 mg/m2/day~* Route: IV~* Schedule: Days 1-5~* Duration: One cycle"

Trial Locations (1)

66205

University of Kansas Cancer Center - Clinical Research Center, Fairway

All Listed Sponsors
lead

Tara Lin

OTHER

NCT02914977 - Low-Dose Daunorubicin in Relapsed/Refractory Acute Leukemia | Biotech Hunter | Biotech Hunter